The future of healthcare
Diabetes Type II
• Resistance to insulin?
• Failure of islet cells to make insulin?
• Defective transporter of insulin?
• Defective ion channel
• Abnormal adrenergic receptor?
• Abnormal sensing of glucose?
2016 GH Sesi 13 YM The Future of Healthcare
Bebas
42
0
0
Teks penuh
(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)
(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)
(42)
Garis besar
Dokumen terkait
come this problem include more powerful drugs that could facilitate shorter regimen or extend the interval between doses to make DOT more practical and perhaps
Regarding the ability of stem cells to differentiate into insulin producing cells 25-27, besides their immunomodulatory function 28-30, this double-blind placebo controlled clinical
4.4.1 Oxidative Stress Markers in the Pancreas 4.4.1.1 Catalase Figure 16 shows the pattern of distribution of catalase in pancreatic islet cells of normal and diabetic rats after
11 State and federal courts do not make federal common law related to immunity and the act of state doctrine; instead, they are constitutionally obligated to apply customary
Defective high- affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anaemia syndrome fibroblasts.. Raz T, Labay V, Baron D, et al.The spectrum of
Keywords: Waqf Model, Healthcare Delivery System, Management, Research Gap Siti Noorkhairina Sowtali Department of Professional Nursing Studies, Kulliyyah of Nursing, International
The pressures on cultivators to shift have now reached such a stage that Myers 1990, 6, concludes: "With scant understanding of how to make sustainable use of forest ecosystems, these
LIME-deficient T cells are defective in their ability to mi- grate to inflammatory sites As the proliferation and cytokine production of effector T cells turned out to be normal
